NO984196L - FremgangsmÕte for behandling av stoffmisbruk - Google Patents

FremgangsmÕte for behandling av stoffmisbruk

Info

Publication number
NO984196L
NO984196L NO984196A NO984196A NO984196L NO 984196 L NO984196 L NO 984196L NO 984196 A NO984196 A NO 984196A NO 984196 A NO984196 A NO 984196A NO 984196 L NO984196 L NO 984196L
Authority
NO
Norway
Prior art keywords
substance abuse
procedure
treatment
olanzapine
administering
Prior art date
Application number
NO984196A
Other languages
English (en)
Other versions
NO984196D0 (no
Inventor
Jr Charles M Beasley
Kurt Rasmussen
Gary D Tollefson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606615.4A external-priority patent/GB9606615D0/en
Priority claimed from GBGB9606617.0A external-priority patent/GB9606617D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO984196D0 publication Critical patent/NO984196D0/no
Publication of NO984196L publication Critical patent/NO984196L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Disintegrating Or Milling (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Steroid Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)

Abstract

Fremgangsmåte for behandling av stoffmisbruk omfattende administrasjon av en effektiv mengde av olanzapin eller farmasøytisk akseptabel salt derav til en pasient som har behov for dette.
NO984196A 1996-03-11 1998-09-11 FremgangsmÕte for behandling av stoffmisbruk NO984196L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1316096P 1996-03-11 1996-03-11
US1316196P 1996-03-11 1996-03-11
GBGB9606615.4A GB9606615D0 (en) 1996-03-29 1996-03-29 Method for treating alcohol addiction
GBGB9606617.0A GB9606617D0 (en) 1996-03-29 1996-03-29 Method for treating substance abuse
PCT/US1997/003404 WO1997033586A1 (en) 1996-03-11 1997-03-10 Method for treating substance abuse

Publications (2)

Publication Number Publication Date
NO984196D0 NO984196D0 (no) 1998-09-11
NO984196L true NO984196L (no) 1998-11-03

Family

ID=27451428

Family Applications (1)

Application Number Title Priority Date Filing Date
NO984196A NO984196L (no) 1996-03-11 1998-09-11 FremgangsmÕte for behandling av stoffmisbruk

Country Status (15)

Country Link
EP (1) EP1007050B1 (no)
JP (1) JP2000517287A (no)
KR (1) KR19990087714A (no)
CN (1) CN1213308A (no)
AT (1) ATE295731T1 (no)
BR (1) BR9708037A (no)
CA (1) CA2248738A1 (no)
CZ (1) CZ290398A3 (no)
DE (1) DE69733321D1 (no)
IL (1) IL126158A0 (no)
NO (1) NO984196L (no)
NZ (1) NZ331845A (no)
PL (1) PL328924A1 (no)
TR (1) TR199801801T2 (no)
WO (1) WO1997033586A1 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174882B1 (en) 1998-11-23 2001-01-16 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
CA2351718A1 (en) 1998-11-23 2000-06-02 Sepracor Inc. Desmethylolanzapine compositions and methods
WO2000030649A1 (en) * 1998-11-23 2000-06-02 Sepracor Inc. Pharmaceutical compositions containing olanzapine-n-oxide
MXPA03006251A (es) * 2001-01-12 2004-10-15 Innovation Ventures Llc Composicion a base de carbon vegetal activado y metodo para reducir sintomas de resaca asociados con el consumo de bebidas que contienen alcohol.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5605911A (en) * 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US5696115A (en) * 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal

Also Published As

Publication number Publication date
AU2067297A (en) 1997-10-01
AU725940B2 (en) 2000-10-26
EP1007050A4 (en) 2000-06-14
JP2000517287A (ja) 2000-12-26
ATE295731T1 (de) 2005-06-15
KR19990087714A (ko) 1999-12-27
CN1213308A (zh) 1999-04-07
EP1007050B1 (en) 2005-05-18
DE69733321D1 (de) 2005-06-23
IL126158A0 (en) 1999-05-09
NZ331845A (en) 2000-09-29
PL328924A1 (en) 1999-03-01
BR9708037A (pt) 1999-07-27
TR199801801T2 (xx) 1998-12-21
NO984196D0 (no) 1998-09-11
CA2248738A1 (en) 1997-09-18
CZ290398A3 (cs) 1999-10-13
WO1997033586A1 (en) 1997-09-18
EP1007050A1 (en) 2000-06-14

Similar Documents

Publication Publication Date Title
AU6257798A (en) Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
DK0668763T3 (da) Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
HK153996A (en) Use of insulin sensitizing agents to treat hypertension
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
EA199800866A1 (ru) Способ снятия боли
ATA901396A (de) Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
NO984197D0 (no) Fremgangsmåte for behandling av autisme
NO984198L (no) FremgangsmÕte for behandling av aggresjon
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
EA199800820A1 (ru) Способ лечения злоупотребления лекарственными средствами
DE69800906D1 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
EA199800818A1 (ru) Способ лечения бессонницы
EE04951B1 (et) R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine uneh„irete raviks
YU40198A (sh) Postupak za tretiranje zavisnosti od supstance
DK0872238T3 (da) Anvendelse af olanzapin til fremstilling af et medikament til neuroprotektin
UA25399A (uk) Спосіб лікуваhhя хворих гломерулоhефритом

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application